CRB Bio II, ADE Capital Sodical commit €3M seed investment round in Raman Health Technologies

CRB Bio II, a VC Fund managed by CRB Inverbío, and ADE Capital Sodical, have committed a €3M seed investment round in Raman Health Technologies, a new start up company developing a new non invasive diagnostic technology platform based on Raman laser and Infrarred spectroscopy. Its first indication will be for the early diagnosis of Alzheimer disease in a blood sample.

Raman Health, based at the Boecillo Technology Park, is a spin-off of the University of Valladolid Fernando Rull, Professor of Crystallography and Mineralogy of the University of Valladolid is one of the key persons in this project. This financing round will allow the company to achieve its strategic objectives, namely the establishment of a new expanded lab facility to foster the development of the methodology for the detection of spectroscopic biomarkers and the development of a robust diagnostic platform.

Laser to detect Alzheimer
The platform being developed by Raman Health Technologies will be used for the diagnosis of different diseases in a blood sample. In the case of Alzheimer disease, it avoids the need of invasive techniques, like the lumbar punction to obtain cerebrospinal fluid and will provide a significant improvement in costs and logistics compared to Imaging Technologies (NMR or PET). Additionally, based on its capability to identify different biological substances, the spectroscopy of Raman Health Technologies can provide simultaneously information of several biomarkers with just one spectroscopic reading. When compared to other diagnostic technologies, Raman–Laser based spectroscopy is faster, less invasive and cheaper. Additionally no reagents are needed. Raman Health Technologies can change the diagnosis  of complex diseases like Alzheimer.

CRB Bio II third investment
This transaction is the third investment made by CRB Bio II, one of the largest specialized Life Science Funds in Spain, after those made in Oncovision and Amadix, for a total aggregated investment in excess of €3,5M. “This last investment underscores our commitment to invest in disruptive technologies at early stage of development in life sciences. In the case of Raman Health Technologies, this is a very cost-effective technology, with a terrific potential and multiple application areas.” says Pablo Cabello, CSO of CRB Inverbío.

Source: http://www.crbinverbio.com/